Lexeo Therapeutics (LXEO) Net Income towards Common Stockholders (2022 - 2026)

Lexeo Therapeutics has reported Net Income towards Common Stockholders for 5 years, with the latest figure at -$20.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 38.16% year-over-year to -$20.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$89.6 million (up 18.06% YoY) and the FY2025 annual result came in at -$222.1 million, down 125.83% from the prior year.
• Net Income towards Common Stockholders advanced to -$20.2 million in Q1 2026 per LXEO's latest filing, from -$23.0 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$13.4 million in Q2 2023 and troughed at -$32.7 million in Q1 2025.
• A 5-year average of -$21.2 million and a median of -$20.3 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2024 and 2026: Net Income towards Common Stockholders sank 82.73% in 2024, then soared 38.16% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at -$14.6 million in 2022, then rose by 2.68% to -$14.2 million in 2023, then sank by 82.73% to -$25.9 million in 2024, then increased by 11.36% to -$23.0 million in 2025, then climbed by 12.11% to -$20.2 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$20.2 million, -$23.0 million, and -$20.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.